Aceragen

What Aceragen does

Aceragen is a clinical-stage biotechnology company developing therapeutic treatments for rare and ultra-rare diseases, with a primary focus on enzyme replacement therapies (ERT) for lysosomal storage disorders. Founded in 2021 and headquartered in Durham, North Carolina, the company employs 11-50 people and operates a private, asset-acquisition model — it acquires de-risked investigational therapies with existing regulatory designations from other biotechs and advances them through clinical development toward approval.

The company's core product is ACG-801 (formerly RVT-801), an investigational enzyme replacement therapy targeting Farber disease, a lysosomal storage disorder characterized by deficiency of the acid ceramidase enzyme. ACG-801 has received both rare pediatric disease designation and fast track designation from the FDA, and there are currently no approved specific treatments for Farber disease. Aceragen acquired full rights to RVT-801 from Enzyvant in May 2021 for a deal valued at up to $226 million in total consideration. The company expanded its pipeline in November 2021 by acquiring Arrevus, which added additional late-stage rare disease candidates.

Aceragen's business model is centered on acquiring promising investigational therapies, advancing them through clinical development using specialized biotech financing structures, and ultimately commercializing approved rare disease treatments through specialty pharmaceutical distribution channels. The company secured $35 million in product financing from NovaQuest Capital Management in May 2021 specifically to support development of ACG-801. As a clinical-stage company with no approved products, Aceragen is currently pre-revenue. Its go-to-market motion relies on regulatory engagement with agencies such as the FDA for orphan and rare pediatric designations, followed by planned specialty pharmacy distribution for any approved treatments. John Taylor serves as Chief Executive Officer.

Name

Aceragen

Website

https://aceragen.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Aceragen is a clinical-stage biotech developing enzyme replacement therapies for rare and ultra-rare lysosomal storage diseases. Its lead asset, ACG-801, targets Farber disease, a lysosomal storage disorder with no approved treatments, and has received FDA rare pediatric and fast track designations.

Ownership category

akta.pro rank

Product category

Rare Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Enzyme Replacement & Metabolic Disorder Therapies (HLAIAIAB)

akta.pro secondary industry

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

Keywords

• Rare disease therapeutics
• Enzyme replacement therapy
• Lysosomal storage diseases
• Biopharmaceutical development
• Orphan drug development

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Drug Development and Commercialization: Aceragen generates revenue by acquiring promising investigational therapies, advancing them through clinical development, and commercializing approved rare disease treatments. The company secured $35 million in product financing specifically to support development of ACG-801 for Farber disease.

Go-to-market motion1 record

Core offering

Aceragen develops and commercializes late-stage therapeutic candidates for rare and ultra-rare diseases, with its lead asset ACG-801 (formerly RVT-801) being an investigational enzyme replacement therapy for Farber disease, a lysosomal storage disorder. The company acquires de-risked investigational assets and advances them through clinical development and regulatory approval.

Product overview

Aceragen is a biotech company focused on rare disease drug development. Its core product is ACG-801 (formerly RVT-801), an investigational enzyme replacement therapy targeting Farber disease, a lysosomal storage disorder with no approved treatment options. The company expanded its pipeline through the acquisition of Arrevus and secured $35 million in product financing from NovaQuest Capital Management to support clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

• ACG-801 (formerly RVT-801) Investigational enzyme replacement therapy (recombinant acid ceramidase) being developed by Aceragen for the treatment of Farber disease, an ultra-rare lysosomal storage disorder with no approved disease-modifying treatment. The asset holds Rare Pediatric Disease designation and FDA Fast Track designation.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• ArrevuscoreStrategic or Co-development Partner · 2 November 2021Aceragen acquired Arrevus to expand its pipeline in late-stage rare disease treatments. This strategic acquisition enhances Aceragen's position in the rare disease market by adding Arrevus's pipeline assets to the company's portfolio of rare disease therapeutic candidates.
• EnzyvantcoreOEM/ Whitelabel/ Licensing Partner · 3 May 2021Enzyvant sold its preclinical Farber disease therapy RVT-801 to Aceragen. Aceragen secured full rights to the therapy for up to $226 million in total deal value. The therapy, now called ACG-801, is an investigational enzyme replacement therapy targeting acid ceramidase deficiency (Farber disease).

Scale indicators2 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• BioMarin Pharmaceutical: BioMarin is a leading rare disease biotech with a deep enzyme replacement therapy franchise (e.g., Naglazyme, Vimizim, Aldurazyme). It is the closest analog to Aceragen's ERT-focused rare disease strategy.
• Ultragenyx Pharmaceutical: Ultragenyx develops therapies for rare and ultra-rare genetic diseases, including ERT and gene therapy approaches for metabolic disorders. Comparable mission, target patient populations, and asset-acquisition strategy.
• Amicus Therapeutics: Amicus Therapeutics develops ERTs and chaperone therapies for lysosomal storage diseases such as Fabry and Pompe. Directly comparable platform, modality, and patient population focus.

Broad incumbents

• Genzyme (Sanofi): Genzyme pioneered ERT for lysosomal storage diseases (e.g., Cerezyme, Fabrazyme, Myozyme). As a Sanofi division, it sets the standard for rare disease ERT commercialization that Aceragen's pipeline targets.
• Alexion (AstraZeneca Rare Disease): Alexion built a leading rare disease franchise through Soliris/Strensiq, and was acquired by AstraZeneca. Comparable go-to-market model targeting ultra-rare patient populations with high-priced specialty biologics.
• Takeda Pharmaceutical (Shire Rare Disease): Takeda's rare disease franchise (inherited from Shire) includes multiple ERT products (e.g., Replagal, Vpriv, Elaprase). Comparable commercial reach in lysosomal storage disorders and rare disease specialty distribution.

Emerging players

• Orphazyme: Orphazyme was a clinical-stage rare disease biotech focused on therapies for lysosomal storage and neurodegenerative diseases. Comparable target indications and rare disease development model.
• Sarepta Therapeutics: Sarepta focuses on rare disease therapeutics, primarily gene therapy for Duchenne muscular dystrophy. Comparable orphan drug strategy, regulatory engagement, and specialty distribution approach.

Others

• Enzyvant Sciences: Enzyvant is a rare disease biotech that sold RVT-801 (now ACG-801) to Aceragen. Comparable rare disease asset development and commercialization focus.
• NovaQuest Capital Management: NovaQuest provided $35M in product financing to Aceragen. As a specialist biotech financier, it provides an indirect comparable for capital structures used by similar rare disease biotechs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key highlights6 records

Customer concentration

• Xx.com/aceragen

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aceragen